SynCore Biotechnology Co. Ltd. (4192) signed a global contract today (11/8) with Swiss optical instruments company Y-YBar for the global technical development of the next generation in choroidal blood flow velocimetry. Y-YBar will transfer their technology to help SynCoreBio optimize their instruments. Such improvements will allow eye disorders to be diagnosed and treated in their early stages. SynCoreBio will own the rights to sell and manufacture the new generation of instruments globally. Through this contract with Y-YBar, the technology imported by SynCoreBio will accelerate the development of the opthalmologic medical equipment industry in Taiwan and help with early diagnosis of severe chronic eye diseases around the world. This will allow doctors to provide opportunities for early prevention and treatment.